Core Insights - The Finnish National Technical Research Centre, in collaboration with various European research institutions and companies, has discovered multiple plant-based new ingredients with anti-inflammatory and anti-aging properties for sustainable skincare product development [1] Group 1: Research Findings - The InnCoCells project team screened over 100 plant extracts and evaluated their effects on 20 biomarkers related to skin inflammation and aging, identifying approximately 25 candidates with development potential [1] - Notable active substances include: - Extracts from Danish rock cress cell cultures, which exhibit significant anti-inflammatory, anti-aging, and antibacterial activities [1] - Extracts from yellow lantern pepper cell cultures, effective against harmful skin bacteria, including methicillin-resistant Staphylococcus aureus, while showing strong anti-aging activity without skin irritation [1] - Extracts from basil hairy root, demonstrating anti-collagenase and anti-hyaluronidase activities, aiding in delaying skin aging and maintaining moisture balance [1] Group 2: Market Implications - The research results pave the way for the development of a new generation of green sustainable cosmetic ingredients [1] - The project team is currently exploring business models and collaboration mechanisms to expedite the market application of the identified plant-based ingredients [1]

Group 1 - The core viewpoint of the news is that 开拓药业-B (09939) has seen a significant stock price increase of over 8% following the announcement of the completion of a long-term safety trial for its new tyrosinase inhibitor, KT-939, which is designed to inhibit melanin production [1][2] - KT-939 has successfully completed the enrollment of 130 participants in its human safety trial, demonstrating effective inhibition of tyrosinase and showcasing antioxidant and anti-inflammatory properties, which are advantageous for cosmetic efficacy and safety [1] - The company is preparing for the registration application of KT-939, aiming to submit it to the Chinese drug regulatory authority in the third quarter of next year, following positive results from multiple safety and toxicology assessments [1] Group 2 - KT-939 is positioned to become the first domestically developed whitening cosmetic ingredient approved in China, marking a significant milestone in achieving complete independent intellectual property rights in this field [2] - The approval of a similar tyrosinase inhibitor, Thiamidol, in November 2024, highlights the potential market opportunity for KT-939, as it could provide a new option for the domestic and global skin whitening cosmetic market [2]

Group 1: DNV Group in China - DNV Group considers China as one of its most important regions globally, with the Chinese market accounting for approximately 28% of DNV's global business [2] - DNV operates five companies in China, with DNV (China) Ltd. serving as the headquarters, providing inspection and consulting services for new shipbuilding and offshore units [4] - DNV has issued over 8,000 certificates globally, with more than 6,000 certificates issued in China, serving various industries including automotive, aerospace, energy, and food [5] Group 2: Future Developments and Innovations - DNV is involved in around 30 joint development projects annually in China, focusing on new ship types and transformation solutions, particularly in the LNG shipbuilding sector [6] - The company has seen a nearly 30% increase in employee numbers over the past five years and emphasizes the training of local talent [6] - DNV aims to leverage Shanghai's advantages to enhance research and development in artificial intelligence, digital solutions, and alternative fuel technologies [6] Group 3: L'Oréal's R&D Center in China - L'Oréal's R&D center in Shanghai has become the largest and most comprehensive globally, with over 400 scientists and 372 patent applications expected in 2024 [7][10] - The center focuses on providing solutions for skin issues and benefits from Shanghai's thriving e-commerce ecosystem and digitalization [10] - L'Oréal is committed to investing in China, recently partnering with Veminsyn to develop innovative bioactive ingredients and launching a skin health management innovation center [11]